Viral hepatitis remains a major global public health challenge, accounting for approximately 1.4 million deaths annually.Hepatitis B virus (HBV) infection alone contributes substantially to this burden, particularly in low- and middle-income countries where access to timely diagnosis and treatment remains limited. Despite the availability of effective vaccines and antiviral therapies, an estimated 90% of individuals living with HBV worldwide remain unaware of their infection status, perpetuating transmission and increasing the risk of long-term liver complications. This review examines current trends in the laboratory diagnosis of HBV infection, with emphasis on both conventional and emerging diagnostic technologies. A systematic literature review was conducted using PubMed, Scopus, and Google Scholar to identify relevant studies published between 2010 and 2025 on HBV diagnostic methodologies. Traditional diagnostic approaches, including serological markers, biochemical liver function tests, and imaging techniques, remain foundational for assessing infection status, immune response, and liver disease progression. However, molecular diagnostics have become central to HBV management, with quantitative detection of HBV DNA and RNA now regarded as the gold standard for viral load monitoring and therapeutic decision-making. Advances in molecular diagnostics span multiple generations, including real-time quantitative polymerase chain reaction (qPCR), isothermal amplification technologies, HBV RNA quantification, and next-generation sequencing (NGS). These innovations offer enhanced sensitivity and specificity, improved disease monitoring, rapid turnaround times, high-throughput capabilities, and expanded applications such as genotyping and antiviral resistance detection. Despite these advancements, significant challenges persist, notably high costs, infrastructure demands, lack of standardization, and limited accessibility in underserved populations. Achieving the World Health Organization’s 2030 hepatitis B elimination targets will require expanding access to affordable, accurate, and simplified diagnostic tools alongside strengthened health systems, workforce training, and public awareness initiatives. Continued technological innovation and global collaboration remain essential to reducing diagnostic gaps and improving outcomes for millions affected by HBV worldwide.